Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: A brief technical report

Role of PET/CT in Treatment Planning for Head and Neck Cancer Patients Undergoing Definitive Radiotherapy

“…They reported that nodal volume parameter was decreased in 3 cases, increased in 9 cases and was unchanged in 3 cases. They also stated that there was no significant difference in terms of nodal involvement areas (Heron DE, et al 2004). In our study, GTVLNPET/CT was larger in 20 cases (54%) and smaller in 12 cases (32.5%) when compared to GTVLN CT .…”

“…There are studies reporting both an increase and a decrease in the target volume (Daisne et al, 2004;Heron et al, 2004;Van Baardwijk, 2004;Paulino et al, 2005;Schwartz et al, 2005). In the literature, this change in the GTV is reported as mostly decreasing.…”

“…However, the GTV values calculated using PET were found to be decreased in patients with tumors in the larynx, oropharynx and hypopharynx (Daisne JF et al 2004). Heron et al reported that the GTV of primary tumors was decreased in 14 cases and increased in 3 cases (a total of 21 cases) using PET/CT (Heron DE, et al 2004). In a study by Van Baardwijket al consisting 16 patients, comparing GTV PET/CT and GTV CT results, it was found that the GTV PET/CT values were significantly smaller (Van Baardwijk, 2004).…”

Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers

“…However, when used together MRI, CT, and PET each can add complimentary data to improve tumor delineation [25]. While most studies examining PET alone based GTVs are usually smaller then their counterpart CT based GTVs, in ∼25% of patients of cases the additional information obtained from PET can increase the GTV compared to CT alone based GTVs [10][11][12][13]15,[26][27][28]. In addition, this number can increase to up to 64% depending on the SUV threshold used [28].…”

Tomographie par émission de positrons dans la prise en charge des carcinomes épidermoïdes des VADS

“…Selon plusieurs publications, la prise en compte des données de la TEP-FDG a entraîné un changement de protocole thérapeutique dans environ 20 % des cas. Ces changements concernent plus le traitement des aires ganglionnaires (aboutissant le plus souvent à une augmentation qu'à une diminution des champs d'irradiation initialement prévus) que celui de la tumeur [14]. Cette application est encore du domaine de la recherche ; d'autres études sont nécessaires pour mieux préciser les limites des lésions fournies pas la TEP-TDM.…”